Tailoring therapeutic approaches based on the intricate dynamics between the immune response and CTCs in Luminal A, Luminal B, TNBC, and HER2+BC is essential for optimizing patient outcomes [153]. This evidence concerns the gene ERBB2 and breast cancer.